Summary
Cellular receptors for immunoglobulins (Fc-receptors; FcR) are central mediators of antibody-triggered effector functions. Immune complex (IC) binding to FcRs results in a variety of reactions such as the release of inflammatory mediators, antibody dependent cellular cytotoxicity (ADCC) and phagocytosis of ICs. Analyzing antibody–FcR (Ab–FcR) interactions in vitro is essential to determine the effector mechanisms, binding characteristics and affinity parameters that will impact and predict antibody activity in vivo. The methods described in this chapter include the generation of ICs and soluble FcR variants, as well as ELISA and FACS-based assays to study Ab–FcR interactions.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Glennie, M. J., and van de Winkel, J. G. (2003) Renaissance of cancer therapeutic antibodies. Drug Discov Today 8, 503–10.
Waldmann, T. A. (2003) Immunotherapy: past, present and future. Nat Med 9, 269–77.
Sanz, L., Blanco, B., and Alvarez-Vallina, L. (2004) Antibodies and gene therapy: teaching old ‘magic bullets’ new tricks. Trends Immunol 25, 85–91.
Clynes, R., and Ravetch, J. V. (1995) Cytotoxic antibodies trigger inflammation through Fc receptors Immunity 3, 21–6.
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., and Watier, H. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene Blood 99, 754–8.
Weng, W. K., and Levy, R. (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21, 3940–7.
Weng, W. K., Czerwinski, D., Timmerman, J., Hsu, F. J., and Levy, R. (2004) Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.break J Clin Oncol 22, 4717–24.
Nimmerjahn, F., and Ravetch, J. V. (2005) Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310, 1510–2.
Nimmerjahn, F., and Ravetch, J. V. (2006) Fcgamma receptors: old friends and new family members. Immunity 24, 19–28.
Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., Fox, J. A., and Presta, L. G. (2001) High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276, 6591–604.
Shields, R. L., Lai, J., Keck, R., O’Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H., Presta, L. G., Namenuk, A. K., Rae, J., Briggs, J., Xie, D., Stadlen, A., Li, B., and Fox, J. A. (2002) Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 277, 26733–40.
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., Hanai, N., and Shitara, K. (2003) The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278, 3466–73.
Schuster, M., Umana, P., Ferrara, C., Brunker, P., Gerdes, C., Waxenecker, G., Wiederkum, S., Schwager, C., Loibner, H., Himmler, G., and Mudde, G. C. (2005) Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering. Cancer Res 65, 7934–41.
Maenaka, K., van der Merwe, P. A., Stuart, D. I., Jones, E. Y., and Sondermann, P. (2001) The human low affinity Fcgamma receptors IIa, IIb, and III bind IgG with fast kinetics and distinct thermodynamic properties. J Biol Chem 276, 44898–904.
Nimmerjahn, F., Bruhns, P., Horiuchi, K., and Ravetch, J. V. (2005) FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23, 41–51.
Ferrara, C., Stuart, F., Sondermann, P., Brunker, P., and Umana, P. (2006) The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem 281, 5032–6.
Getahun, A., and Heyman, B. (2006) How antibodies act as natural adjuvants. Immunol Lett 104, 38–45.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Humana Press Inc.
About this protocol
Cite this protocol
Nimmerjahn, F., Ravetch, J.V. (2008). Analyzing Antibody–Fc-Receptor Interactions. In: Ewbank, J., Vivier, E. (eds) Innate Immunity. Methods in Molecular Biology™, vol 415. Humana Press. https://doi.org/10.1007/978-1-59745-570-1_9
Download citation
DOI: https://doi.org/10.1007/978-1-59745-570-1_9
Publisher Name: Humana Press
Print ISBN: 978-1-58829-746-4
Online ISBN: 978-1-59745-570-1
eBook Packages: Springer Protocols